Regeneus is Solidifying Out-Licensing Partnering and Looking to Commence a Japanese Phase II Trial

Monday, 7 August 2017

Interview with Japan Chemical Daily

Cellular Therapy for Knee OA

Mr. John Martin, CEO of the Australian regenerative medicine venture company, Regeneus, agreed to be interviewed by this newspaper and relayed his plan to locate an out-license partner for the firm’s Knee Osteoarthritis (OA) cellular therapy. Progenza is garnering interest from a number of companies on the back of Regeneus’ Australian Phase I data, which showed possible disease modifying properties. AGC Asahi Glass already has exclusive manufacturing rights for Progenza in Japan.